Phase 4 N=111 Treatment of Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Progression-free Survival — 35; 27 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1
Phase 2 N=65 A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Peripheral T-Cell Lymphoma
Primary: Tumor Response (Central Assessment) — 19.3; 45.6 percentage of participants
Phase 2 N=34 S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Overall Survival Rate — 31 percentage of participants
Phase 2 N=49 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Lymphoma, T-Cell, Peripheral
Primary: Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants — 63.3; 46.9; 40.8; 40.8 Percentage of participants
Phase 2 N=53 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Lymphoma
Primary: 3 Year Progression-Free Survival Rate — 30 percentage of participants
Phase 3 N=271 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Phase 2 N=44 Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative · Anaplastic Large Cell Lymphoma, ALK-Positive · Hepatosplenic T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP — 10 milligrams
Phase 2 N=13 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Phase 2 N=65 Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Relapsed or Refractory Peripheral T-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 56.3; 7.1; 40.0; 0.0 percentage of participants — p=0.000
Phase 2 N=131 A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an…
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=4 Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Phase 2 N=21 CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Previously Untreated Peripheral T-cell Lymphoma
Primary: Complete Response Rate — 75 percentage of participants
Phase 2 N=129 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Objective Response Rate — 25.8 percentage of participants
Phase 2 N=42 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose — 0; 0; 0; 0 Participants
Phase 2 N=55 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Peripheral T-Cell Lymphoma (PTCL)
Primary: Objective Response Rate — 21 Participants
Phase 1 N=13 E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD) — 9 ug/kg/day
Phase 2 N=131 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Phase 2 N=42 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Phase 3 N=71 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Refractory Peripheral T-Cell Lymphoma · Relapsed T-Cell Lymphoma
Primary: Objective Response Rate(ORR) by International Working Group Criteria — 37 Participants
Phase 1 N=12 A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=131 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Hodgkin Disease · Peripheral T Cell Lymphoma
Primary: Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C) — 93; 95; 85 Percentage of participants
Phase 2 N=49 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Primary: Number of Patients That Achieved a Complete Response or a Partial Response (PR) — 32 participants
Phase 2 N=32 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Phase 2 N=46 Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Lymphoma
Primary: 12-Month Progression-Free Survival (PFS) — 0.44 probability
Phase 1 N=11 Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Phase 3 N=253 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants
Phase 2 N=33 A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Peripheral T-cell Lymphoma
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria — 53.8; 53.8 percentage of participants